Pulmonary toxicity of immune checkpoint immunotherapy
Journal of Clinical Investigation · 16.01.2024 · 134 (2)
DOI: 10.1172/jci170503 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.01.2024. Verfasst von Mohammad I Ghanbar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary & Critical Care Medicine, Department of Medicine, and. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological, Pneumonia. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer remains a leading cause of mortality on a global scale. Lung cancer, specifically non-small cell lung cancer (NSCLC), is a prominent contributor to this burden. The management of NSCLC has advanced substantially in recent years, with immunotherapeutic agents, such as immune checkpoint inhibitors (ICIs), leading to improved patient outcomes. Although generally well tolerated, the administration of ICIs can result in unique side effects known as immune-related adverse events (irAEs). The occurrence of irAEs involving the lungs, specifically checkpoint inhibitor pneumonitis (CIP), can have a profound effect on both future therapy options and overall survival. Despite CIP being one of the more common serious irAEs, limited treatment options are currently available, in part due to a lack of understanding of the underlying mechanisms involved in its development. In this Review, we aim to provide an overview of the epidemiology and clinical characteristics of CIP, followed by an examination of the emerging literature on the pathobiology of this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary & Critical Care Medicine, Department of Medicine, and.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zitieren
APA
Ghanbar, M. I., & Suresh, K. (2024). Pulmonary toxicity of immune checkpoint immunotherapy. Journal of Clinical Investigation, 134(2). https://doi.org/10.1172/jci170503
Vancouver
Ghanbar MI, Suresh K. Pulmonary toxicity of immune checkpoint immunotherapy. Journal of Clinical Investigation. 2024;134(2). doi:10.1172/jci170503
BibTeX
@article{Ghanbar2024,
author = {Ghanbar, Mohammad I and Suresh, Karthik},
title = {Pulmonary toxicity of immune checkpoint immunotherapy},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {2},
doi = {10.1172/jci170503}
}
EUVIMED